Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$31.36 - $39.99 $30,826 - $39,310
983 Added 10.36%
10,470 $337,000
Q1 2024

May 06, 2024

SELL
$31.23 - $40.91 $15,115 - $19,800
-484 Reduced 4.85%
9,487 $368,000
Q4 2023

Feb 14, 2024

BUY
$21.16 - $30.8 $67,712 - $98,560
3,200 Added 47.26%
9,971 $306,000
Q3 2023

Nov 07, 2023

BUY
$21.23 - $24.28 $4,246 - $4,856
200 Added 3.04%
6,771 $151,000
Q2 2023

Aug 08, 2023

SELL
$21.06 - $24.0 $138,574 - $157,920
-6,580 Reduced 50.03%
6,571 $141,000
Q1 2023

May 12, 2023

BUY
$23.0 - $29.88 $234,738 - $304,955
10,206 Added 346.55%
13,151 $315,000
Q4 2022

Feb 13, 2023

SELL
$16.14 - $23.55 $22,951 - $33,488
-1,422 Reduced 32.56%
2,945 $68,000
Q3 2022

Nov 07, 2022

BUY
$15.46 - $20.1 $67,513 - $87,776
4,367 New
4,367 $69,000
Q1 2021

May 14, 2021

SELL
$19.25 - $26.1 $40,425 - $54,810
-2,100 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$17.83 - $22.29 $37,443 - $46,809
2,100 New
2,100 $42,000
Q3 2019

Nov 12, 2019

SELL
$10.16 - $13.28 $8,128 - $10,624
-800 Closed
0 $0
Q2 2019

Aug 13, 2019

BUY
$10.62 - $16.59 $8,496 - $13,272
800 New
800 $10,000
Q1 2019

May 13, 2019

SELL
$13.58 - $18.72 $62,196 - $85,737
-4,580 Closed
0 $0
Q4 2018

Feb 13, 2019

BUY
$14.78 - $19.68 $576 - $767
39 Added 0.86%
4,580 $78,000
Q3 2018

Nov 13, 2018

BUY
$14.16 - $24.3 $64,300 - $110,346
4,541 New
4,541 $66,000
Q2 2018

Aug 13, 2018

SELL
$21.79 - $28.29 $95,200 - $123,599
-4,369 Closed
0 $0
Q1 2018

May 11, 2018

SELL
$18.15 - $29.21 $72,436 - $116,577
-3,991 Reduced 47.74%
4,369 $111,000
Q4 2017

Feb 12, 2018

BUY
$9.3 - $19.14 $77,748 - $160,010
8,360
8,360 $154,000

Others Institutions Holding COLL

About COLLEGIUM PHARMACEUTICAL, INC


  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $1.11B
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track This Portfolio

Track Quantbot Technologies LP Portfolio

Follow Quantbot Technologies LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

News

Stay updated on Quantbot Technologies LP with notifications on news.